Tirzepatide 7.5 mg: Mid-Range Dose (Weeks 9-12 or Maintenance)
7.5 mg is tirzepatide's third titration step and a valid long-term maintenance setpoint — more potent than 5 mg, more tolerable than 10-15 mg.
Tirzepatide 7.5 mg weekly is the third step in the Zepbound titration. It's also one of five FDA-approved maintenance doses (5, 7.5, 10, 12.5, 15 mg) — patients can hold here long-term as a clinically reasonable setpoint. The 7.5 mg dose offers more weight loss than 5 mg without the increased side-effect intensity of 10-15 mg.
Where 7.5 mg sits in the titration
Standard Zepbound schedule: 2.5 mg (wks 1-4) → 5 mg (wks 5-8) → 7.5 mg (wks 9-12) → 10 mg (wks 13-16) → 12.5 mg (wks 17-20) → 15 mg (wks 21+). Most patients reach 7.5 mg by week 9 if they've tolerated the prior two steps. The dose doubles in receptor activation vs the 2.5 mg starter while staying below the maximum 15 mg.
Side effects + clinical response at 7.5 mg
Each step typically produces 5-10 days of transient GI symptom increase post-dose-change (nausea, fatigue, constipation, diarrhea), then symptom decrease as the gut adapts. The 7.5 mg dose can produce more frequent nausea than 5 mg but is generally manageable. Patients who tolerated 5 mg well usually transition through 7.5 mg without major issues.
Maintenance at 7.5 mg as a strategic option
When holding at 7.5 mg makes sense
- • Steady weight loss at 0.5-1% body weight per week
- • Strong appetite suppression — don't feel you need more
- • Tolerating side effects well at this dose
- • Concerned about facial volume loss from faster rate of loss at higher doses
- • Within 10-20 lbs of goal weight
Continue with Trimi
$125/month annual plan covers any tirzepatide titration dose. Same active ingredient as Zepbound and Mounjaro.
Start your visitFAQs
When do I escalate to tirzepatide 7.5 mg?
Week 9, per the standard titration. After 4 weeks at 2.5 mg starter (wks 1-4) and 4 weeks at 5 mg (wks 5-8), most patients move to 7.5 mg in weeks 9-12. This is an intermediate step between the first-therapeutic 5 mg dose and the higher 10/12.5/15 mg levels.
Is 7.5 mg an FDA-approved maintenance dose?
Yes — Zepbound is FDA-approved at 5, 7.5, 10, 12.5, and 15 mg as either titration steps or maintenance doses. Per Zepbound prescribing information, any of these is a valid long-term setpoint depending on response and tolerability.
What weight loss should I expect at 7.5 mg?
SURMOUNT-1 didn't include a dedicated 7.5 mg maintenance arm, but interpolation between the 5 mg (15.0%) and 10 mg (19.5%) groups suggests ~17% mean body weight reduction at 7.5 mg long-term. Patients typically see steady weight loss continuing through this titration block.
Side effects at 7.5 mg vs 5 mg?
Each titration step causes 5-10 days of transient GI symptom increase. At 7.5 mg, nausea, vomiting, and diarrhea may be slightly more frequent than 5 mg — but generally manageable for patients who tolerated 5 mg well. Severe symptoms warrant slowing or pausing escalation.
Can I maintain at 7.5 mg long-term?
Yes — clinically valid. Patients responding well to 7.5 mg with steady weight loss and good tolerance often hold here rather than escalating further. The 7.5 mg dose offers a balance: meaningfully more effect than 5 mg, fewer side effects than 10-15 mg. Trimi clinicians individualize this decision.
Should I escalate from 7.5 mg to 10 mg?
Depends on goals and response. If you've plateaued at 7.5 mg and want additional weight loss, escalation to 10 mg is standard. If you're losing well and tolerating side effects, holding at 7.5 mg is reasonable. Patients concerned about facial volume loss often prefer to hold at 7.5 mg.
Related reading
Disclaimer: Informational, not medical advice. Compounded tirzepatide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. **The FDA does not review or approve any compounded medications for safety or effectiveness.